Filing Flows › ARS Pharmaceuticals (SPRY) › Q3 2026 › vs Q2 2026
ARS Pharmaceuticals (SPRY) Q3 2026 vs Q2 2026 (quarter over quarter)
ARS Pharmaceuticals's revenue rose $4.1M (+12%) from $33.7M in Q2 2026 to $37.7M in Q3 2026. The biggest changes: Product +$7.2M (+27%); Revenue Under Supply Agreements −$4.8M (-64%); Revenue Under Collaboration Agreements +$1.6M (29×).
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product | $33.4M | $26.2M | $7.2M | +27% |
| Revenue Under Supply Agreements | $2.6M | $7.4M | −$4.8M | -64% |
| Revenue Under Collaboration Agreements | $1.7M | $57K | $1.6M | 29× |
| Revenue | $37.7M | $33.7M | $4.1M | +12% |
| Net loss | $35.6M | $62.3M | −$26.8M | -43% |
| Costs & expenses | $73.3M | $96.0M | −$22.7M | -24% |
| Operating costs | $71.9M | $95.1M | −$23.2M | -24% |
| Interest & other, net | $1.4M | $874K | $542K | +62% |
| Research & development | $18.3M | $4.7M | $13.6M | +289% |
| SG&A | $43.5M | $77.6M | −$34.1M | -44% |
| Other operating costs | $10.1M | $12.8M | −$2.7M | -21% |
| Operating cash sources | $42.2M | $73.7M | −$31.5M | -43% |
| Depreciation & amortization | $415K | $416K | −$1K | -0.2% |
| Share-based compensation | $8.1M | $12.4M | −$4.3M | -34% |
| Cash used in operations | $33.7M | $60.9M | −$27.2M | -45% |
| Net loss absorbed | $35.6M | $62.3M | −$26.8M | -43% |
| Working capital & other | $6.7M | $11.4M | −$4.7M | -42% |
Questions
How much did ARS Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
ARS Pharmaceuticals's revenue rose $4.1M (+12%) from $33.7M in Q2 2026 to $37.7M in Q3 2026.
What drove ARS Pharmaceuticals's revenue change in Q3 2026?
Product +$7.2M (+27%); Revenue Under Supply Agreements −$4.8M (-64%); Revenue Under Collaboration Agreements +$1.6M (29×).